All In Biotech

Drug Trial Radar · NCT05755191

A Study to Assess NEU-411 in Healthy Participants

A Phase 1, Single and Multiple Ascending Dose and Food Effect Study of NEU-411 Administered Orally to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 147 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

147

Actual

Start

May 13, 2023

Primary completion

Jun 3, 2024

Study completion Jun 3, 2024

Sponsor

Lead sponsor
Neuron23 Inc.Industry
Sponsor type
Industry
First posted
Mar 6, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, randomized, double-blind, placebo-controlled, single ascending dose (SAD), food effect (FE),multiple ascending dose (MAD), drug-drug interaction study, and bioavailability - bio-equivalence study of orally administered NEU-411 in healthy subjects

Conditions

  • Healthy

Interventions

  • NEU-411Drug

    Oral Doses

  • PlaceboDrug

    Oral Doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability of single dosing, food effect and multiple oral doses of NEU-411 in healthy subjectsTime frame: Up to 7 days of dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • New Zealand Clinical Research

    Christchurch, New Zealand

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.